LeMaitre Vascular (NASDAQ:LMAT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

Several other research firms have also issued reports on LMAT. Roth Mkm reaffirmed a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Barrington Research restated an “outperform” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research note on Friday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th. Finally, Wells Fargo & Company decreased their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Trading Down 1.7%

LMAT opened at $91.38 on Friday. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average of $85.71 and a 200-day moving average of $88.11. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $105.55. The stock has a market cap of $2.07 billion, a PE ratio of 39.39, a PEG ratio of 2.06 and a beta of 0.72.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently added to or reduced their stakes in the stock. Vest Financial LLC increased its position in LeMaitre Vascular by 60.0% during the third quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier’s stock valued at $4,925,000 after acquiring an additional 21,102 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at about $1,101,000. First Trust Advisors LP grew its stake in shares of LeMaitre Vascular by 52.7% during the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after purchasing an additional 211,280 shares during the period. Envestnet Asset Management Inc. increased its position in shares of LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock valued at $25,293,000 after purchasing an additional 19,447 shares during the last quarter. Finally, Congress Asset Management Co. lifted its stake in shares of LeMaitre Vascular by 2.7% in the 3rd quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock worth $60,580,000 after purchasing an additional 18,298 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.